Please assess the completion status of the following clinical trial:

Trial Title: A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any study-related activities. Study-related activities are any procedures related to recording of data according to the protocol.~* The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before, and independently from, the decision to include the patient in this study.~* Male or female, age above or equal to 18 years at the time of signing informed consent.~* Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than Ryzodeg® for at least 26 weeks prior to signing informed consent.~* Available and documented HbA1c value for 12 weeks or less prior to signing informed consent.~Exclusion Criteria:~* Hypersensitivity to the active substance or to any of the excipients as specified in the Ryzodeg® local label.~* Previous participation in this study. Participation is defined as signed informed consent.~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.~* Previous treatment with Ryzodeg®.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ryzodeg® as per local practice (Type: None): Real-world population of patients with Diabetes Mellitus, Type 2 (T2DM), who have been initiated or switched to Ryzodeg® from previous antihyperglycaemic treatment according to local clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).